Form 4 for ELVN Enliven Therapeutics, Inc.
Accepted 2021-07-28 00:00:00 ET · period of report 2021-07-16 · accession 0001209191-21-048395 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2021-07-28 | 2021-07-16 | ELVN | Chin Mark | Dir | P - Purchase | $6.00 | +1.33M | 2.34M | +132% | +$8.00M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-07-16 | P | A | 1,333,333 | $6.00 | 2,344,072 | I By entities affiliated with Arix Bioscience plc | — | — | (F1) The shares are directly beneficially owned by Arix Bioscience Holdings Limited ("Arix Ltd."). Arix Bioscience Plc ("Arix Plc") is the sole owner and parent of Arix Ltd. and may be deemed to indirectly beneficially own the shares held by Arix Ltd. Mr. Chin is a managing director of Arix plc. Each of Arix plc and Mr. Chin disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests therein. |